Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics Inc (SPRO)
NASDAQ:SPRO
Total Valuation
Spero Therapeutics has a market cap or net worth of $33.54M. The enterprise value is $7.58M.
Market Cap$33.54M
Enterprise Value$7.58M
Share Statistics
Spero Therapeutics has 55.90M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55.90M
Owened by Insiders7.88%
Owened by Instutions18.07%
Financial Efficiency
Spero Therapeutics’s return on equity (ROE) is -1.49 and return on invested capital (ROIC) is -116.05%.
Return on Equity (ROE)-148.66%
Return on Assets (ROA)-62.03%
Return on Invested Capital (ROIC)-116.05%
Return on Capital Employed (ROCE)-119.35%
Revenue Per Employee$2,984,906.25
Profits Per Employee$109,781.25
Employee Count32
Asset Turnover0.43
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Spero Therapeutics is -0.81. Spero Therapeutics’s PEG ratio is <0.01.
PE Ratio-0.81
PS Ratio1.16
PB Ratio1.21
Price to Fair Value1.21
Price to FCF-2.37
Price to Operating Cash Flow-2.37
PEG Ratio<0.01
Income Statement
In the last 12 months, Spero Therapeutics had revenue of $95.52M and earned $3.51M in profits. Earnings per share was $0.08.
Revenue$95.52M
Gross Profit$100.54M
Operating Income-$7.86M
Pretax Income$3.61M
Net Income$3.51M
EBITDA-972.25K
Earnings Per Share (EPS)0.08
Cash Flow
In the last 12 months, operating cash flow was -$17.54M and capital expenditures $0.00, giving a free cash flow of -$17.54M billion.
Operating Cash Flow-$17.54M
Free Cash Flow-$17.54M
Free Cash Flow per Share-$0.31
Dividends & Yields
Spero Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-42.12%
Earnings Yield-123.19%
Stock Price Statistics
Beta1.52
52-Week Price Change-60.78%
50-Day Moving Average0.77
200-Day Moving Average1.11
Relative Strength Index (RSI)35.02
Average Volume (3m)155.20K
Important Dates
Spero Therapeutics upcoming earnings date is May 9, 2025, TBA.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 9, 2025
Ex-Dividend Date―
Financial Position
Spero Therapeutics as a current ratio of 2.19, with Debt / Equity ratio of 0.09
Current Ratio2.19
Quick Ratio2.19
Debt to Market Cap0.08
Net Debt to EBITDA0.66
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Spero Therapeutics has paid $5.25K in taxes.
Income Tax$5.25K
Effective Tax Rate0.00%
Enterprise Valuation
Spero Therapeutics EV to EBITDA ratio is -0.10, with an EV/FCF ratio of -0.30.
EV to Sales0.15
EV to EBITDA-0.10
EV to Free Cash Flow-0.30
EV to Operating Cash Flow-0.30
Balance Sheet
Spero Therapeutics has $76.29M in cash and marketable securities with $4.62M in debt, giving a net cash position of -$71.67M billion.
Cash & Marketable Securities$76.29M
Total Debt$4.62M
Net Cash-$71.67M
Net Cash Per Share-$1.28
Tangible Book Value Per Share$0.85
Margins
Gross margin is 100.00%, with operating margin of -152.91%, and net profit margin of -142.91%.
Gross Margin100.00%
Operating Margin-152.91%
Pretax Margin-142.91%
Net Profit Margin-142.91%
EBITDA Margin-152.91%
EBIT Margin0.00%
Analyst Forecast
The average price target for Spero Therapeutics is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.00
Price Target Upside733.33%
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-71.68%
EPS Growth Forecast-397.61%